Paula Briggs

Paula Briggs

Auto-generated profile, based on publicly available information

Paula Briggs

Liverpool Women’s Hospital NHS Foundation Trust, Liverpool, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
CGCatriona Grant
Catriona Grant
MSMarco Serrani
Marco Serrani
KVKai Vogtländer
Kai Vogtländer
SPSusanne Parke
Susanne Parke
PBPaula Briggs
Paula Briggs
Background: Oral contraceptives are still associated with high discontinuation rates, despite their efficacy. There is a wide choice of oral contraceptives available, and the aim of this study was to assess continuation rates, bleeding profile acceptability, and the satisfaction of women in the first year of using a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) versus a progestogen-only pill (POP) in a real-life setting after discontinuing an ethinylestradiol-containing pill. Methods and results: In this prospective, noninterventional, observational study, 3,152 patients were included for the efficacy analyses (n=2,558 women in the E2V/DNG group and n=592 in the POP group (two patients fulfilled the criteria of the efficacy population, but the used product was not known). Women had been taking an ethinylestradiol-containing pill ≥3 months before deciding to switch to the E2V/DNG pill or a POP. Overall, 19.8% (n=506) of E2V/DNG users and 25.8% (n=153) of POP users discontinued their prescribed pill. The median time to discontinuation was 157.0 days and 127.5 days, respectively. Time to discontinuation due to bleeding (P<0.0001) or other reasons (P=0.022) was significantly longer in the E2V/DNG group versus the POP group. The E2V/DNG pill was also associated with shorter (48.7% vs 44.1%), lighter (54% vs 46.1%), and less painful bleeding (91.1% vs 73.7%) and greater user satisfaction (80.7% vs 64.6%) than POP use, within 3–5 months after switch. Conclusion: The E2V/DNG pill was associated with higher rates of continuation, bleeding profile acceptability, and user satisfaction than POP use and may be an alternative option for women who are dissatisfied with their current pill.

23 October 2019 in Post Reproductive Health
Verified
Journal Article
Closed access
PDF file
PBPaula Briggs
Paula Briggs
Genitourinary syndrome of menopause affects approximately 50% of women post-menopause and is under-reported. This review of the condition including established and newer treatment options aspires to empower clinicians to ask about symptoms and be more proactive in their management.

7 January 2013 in BMJ Sexual & Reproductive Health
Verified
Journal Article
Open access
PDF file
PBPaula Elizabeth Briggs
Paula Elizabeth Briggs
CPCecile Aude Praet
Cecile Aude Praet
SHSamantha Charlotte Humphreys
Samantha Charlotte Humphreys
CZChanggeng Zhao
Changgeng Zhao
Objectives: Combined hormonal contraceptives (CHCs) are the most widely prescribed contraceptive methods in the UK; however, their use is associated with significant cardiovascular risk for women with some medical conditions and risk factors. The objective of this study was to assess the potential change in CHC prescribing among higher-risk women following publication of the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) in 2006. Methods: A cross-sectional study was conducted using the General Practice Research Database to analyse UK women aged 15–49 years who were prescribed CHCs during the period 2004–2010. Of women prescribed CHCs, those at higher risk of cardiovascular events (with UKMEC Category 3 or 4 risk factors) were identified. The percentage of higher-risk CHC users, among all CHC users, in 2005 (pre-UKMEC) was compared to that in 2010 (post-UKMEC). Results: The percentage of higher-risk CHC users significantly decreased by 0.8% (95% CI 0.68% to 1.02%) following publication of UKMEC [8.1% (95% CI 7.98% to 8.22%) in 2005 vs 7.3% (95% CI 7.14% to 7.38%) in 2010; p<0.001]. However, an estimated 1 74 472 women in the UK were prescribed CHCs in 2010 despite having Category 3 or 4 risk factors. The most common Category 3 or 4 risk factors were body mass index ≥35 kg/m2, hypertension and smoking in women aged ≥35 years. Conclusions: Despite the observed reduction in prescribing of CHCs to higher-risk women after publication of UKMEC, a large number of women with Category 3 or 4 risk factors are still prescribed CHCs. The increased risk of cardiovascular events is unnecessary for many of these women given the availability of alternative contraceptive methods.

4 November 2025 in Menopause
Verified
Journal Article
Open access
CSClaudio N. Soares
Claudio N. Soares
PBPaula Briggs
Paula Briggs
CDCarina Dinkel-Keuthage
Carina Dinkel-Keuthage
NSNils Schoof
Nils Schoof
CMCarsten Moeller
Carsten Moeller
PMPauline M. Maki
Pauline M. Maki
Objectives: To quantify the burden of sleep disturbances on health-related quality of life (HRQoL) and mental well-being in perimenopausal and postmenopausal women with/without co-occurring vasomotor symptoms (VMS). Methods: Perimenopausal and postmenopausal women aged 40 to 65 years who participated in the National Health and Wellness 2019/2021 (US; N=27,621) and 2017/2020 cross-sectional surveys (France, Germany, Italy, Spain, UK; N=20,220) were included. Patient-reported outcomes were HRQoL (Short-Form Health Survey physical and mental component summary scores, EuroQol Visual Analogue Scale, EQ-5D-5L), depression (Patient Health Questionnaire-9), and anxiety (Generalized Anxiety Disorder-7 assessment). Associations between self-reported sleep disturbances and/or VMS and study outcomes were evaluated using generalized multivariable linear regression. Results: Among perimenopausal women, sleep disturbances were reported by 61.7% (US) and 60.6% (Europe) with VMS, and 38.0% (US) and 40.8% (Europe) without VMS. Among postmenopausal women, sleep disturbances were reported by 66.7% (US) and 63.4% (Europe) with VMS, and 44.5% (US) and 40.9% (Europe) without VMS. Compared with women with neither symptom, perimenopausal and postmenopausal women with sleep disturbances had worse HRQoL ( P <0.001) and higher (worse) depression and anxiety scores ( P <0.05 perimenopausal, P <0.001 postmenopausal) irrespective of VMS. In addition, among postmenopausal women, those with sleep disturbances alone had worse HRQoL and higher (worse) depression and anxiety scores than those with VMS alone ( P <0.001). Conclusions: Sleep disturbance was common among perimenopausal and postmenopausal women irrespective of VMS, and independently associated with negative effects on HRQoL, depression, and anxiety. Effective treatments for sleep disturbances and VMS in menopausal women are needed to mitigate the associated burden and improve well-being.

25 November 2021 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
PBPaula Briggs
Paula Briggs
GDGayathri Delanerolle
Gayathri Delanerolle
RBRachel Burton
Rachel Burton
JSjianqin shi
jianqin shi
HHHaitham Hamoda
Haitham Hamoda
DHDharani K. Hapangama
Dharani K. Hapangama
Other hurdles to accessing treatment include limited research, the cost of treatment, and patients’ fear of hormonal treatment options.1

1 February 2022 in Post Reproductive Health
Verified
Journal Article
Closed access
PBPaula Briggs
Paula Briggs
This guidance refers to urogenital atrophy, a chronic and progressive condition due to estrogen deficiency, most commonly associated with the menopause. There is a potential negative impact on all urogenital tissue quality including the vulva, vagina, bladder and urethra. Symptoms may not become apparent for several years after the menopause and therefore any association is lost, with women accepting symptoms as a normal part of the aging process. There may be reluctance to discuss symptoms with a clinician and this is likely to be linked with under diagnosis and under treatment. Urogenital atrophy has been described as a silent epidemic with lack of awareness affecting an accurate diagnosis and access to treatment. Whilst vaginal estrogen (also referred to as local estrogen) therapy is the best-known treatment, newer drugs and interventions are now available.